Search Results

You are looking at 91 - 100 of 149 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management

James L. Mohler

large reduction in biochemical recurrence. 4 In RTOG 86-10, which evaluated RT after 3 months of ADT, the combination led to a reduction in the rates of prostate-specific antigen (PSA) failure, metastases, and cancer-specific mortality and showed a

Full access

No Money, Mo’ Problems: Financial Toxicity in the Realm of Cancer Screening

Arjun N. Patel and Jeffrey M. Sutton

denied having undergone colonoscopy and prostate-specific antigen (PSA) blood testing for colon and prostate cancer screening, respectively. Of 13,439 total responses, 69.03% of men and women aged >50 years had undergone colonoscopy and 70.94% of men aged

Full access

Proton Therapy in an Era of Cost Containment

Joseph M. Herman

, how can improvement be measured? In some cancers it is based on “hard outcomes,” such as survival. Other surrogates of improvement include tumor markers (prostate-specific antigen), toxicity, and QOL. What if clinical trials show that protons improve

Full access

NCCN Guidelines Updates: Management of Prostate Cancer

James L. Mohler and Emmanuel S. Antonarakis

personalized according to end-of-induction prostate-specific antigen [PSA] levels,” Dr. Mohler said. New Controversies Treatment of the primary tumor in patients diagnosed with low-volume metastatic disease is controversial, with advocates on both sides of the

Full access

Androgen Deprivation Therapy for Advanced Prostate Cancer: Can Evolution Be Accelerated?

James L. Mohler

randomized to immediate continuous ADT or observation. In the immediate ADT arm of 47 patients, 30 remained alive, 29 of whom were recurrence-free and 26 of whom were prostate-specific antigen failure-free after a median follow-up of 11.9 years (range, 9

Full access

Differences in Patient Screening Mammography Rates Associated With Internist Gender and Level of Training and Change Following the 2009 U.S. Preventive Services Task Force Guidelines

Dawn J. Brooks

counseling: an analysis of male and female patients' health care experiences . Med Care 2001 ; 39 : 1281 – 1292 . 17. Kerfoot B Holmberg E Lawler E . Practitioner-level determinants of inappropriate prostate-specific antigen screening . Arch

Full access

Management of Metastatic Castration-Resistant Prostate Cancer

Presented by: Sandy Srinivas

In newly diagnosed patients, NGI can be considered when conventional imaging is equivocal or negative with continued high suspicion of metastatic disease. For biochemically recurrent prostate cancer, NGI should be considered for a prostate-specific

Full access


for urinary incontinence and erectile dysfunction with tools such as the UCLA Prostate Cancer Index questions and the Sexual Health Inventory for Men (SHIM) ○ Treatment Team: Prostate-specific antigen has been measured in the last 12 months for

Full access

Risk Stratification and Selection of Management Strategy for Localized Prostate Cancer

Presented by: Alice Yu

in the intermediate-risk category based on clinical stage had lower recurrence rates compared with those categorized by Gleason score 7 or prostate-specific antigen (PSA) level (10–20 ng/mL). To address this heterogeneity, the NCCN risk

Full access

Management of Metastatic Prostate Cancer

Presented by: Archana Ajmera, Rana R. McKay, and Kelly L. Stratton

with an elevated prostate-specific antigen (PSA) level who was diagnosed with a poorly differentiated adenocarcinoma with a Gleason score of 10; all 12 cores appeared to be involved. Prostate-specific membrane antigen (PSMA) PET imaging revealed